
Altimmune Investor Relations Material
Latest events

Study Result
Altimmune
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Altimmune Inc
Access all reports
Altimmune, Inc. engages in the development of immunotherapeutics for infectious and chronic diseases. The company focuses on the development of vaccines and therapeutics for influenza, anthrax and COVID-19. It offers HepTcell, a vaccine candidate to treat Chronic Hepatitis B; AdCOVID, which is an intranasal antigen vaccine to fight COVID-19; NasoVAX, a single dose flu vaccine; T-COVID, an intranasal immune modulating therapeutic candidate; and NasoShield, an anthrax vaccine product candidate. The company was founded by Vipin K. Garg on April 15, 2005 and is headquartered in Gaithersburg, MD.
Latest articles
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
)
500 Years of Craft, One Family Legacy: Beretta Holding's Global Expansion
How Beretta Holding managed to transform from a 16th-century gun barrel producer into a global industrial group while preserving 500 years of legacy.
27 Jun 2025
)
Shuntaro Furukawa: The Sixth President of Nintendo
Shuntaro Furukawa, Nintendo's sixth president, went from a childhood fan to leading the company through global expansion and the launch of Switch 2.
23 Jun 2025
Ticker symbol
ALT
Country
🇺🇸 United States